Karyopharm Therapeutics (KPTI) Competitors $6.58 -0.07 (-0.98%) As of 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KPTI vs. HUMA, SGMT, ALEC, PRQR, IMMP, ENGN, SOPH, OGI, TKNO, and EDITShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Humacyte (HUMA), Sagimet Biosciences (SGMT), Alector (ALEC), ProQR Therapeutics (PRQR), Prima BioMed (IMMP), enGene (ENGN), SOPHiA GENETICS (SOPH), Organigram Global (OGI), Alpha Teknova (TKNO), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. Its Competitors Humacyte Sagimet Biosciences Alector ProQR Therapeutics Prima BioMed enGene SOPHiA GENETICS Organigram Global Alpha Teknova Editas Medicine Humacyte (NASDAQ:HUMA) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations. Which has more risk and volatility, HUMA or KPTI? Humacyte has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Do insiders & institutionals believe in HUMA or KPTI? 44.7% of Humacyte shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 5.1% of Humacyte shares are owned by company insiders. Comparatively, 3.0% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher earnings and valuation, HUMA or KPTI? Karyopharm Therapeutics has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyte$1.57M148.79-$148.70M-$0.45-3.28Karyopharm Therapeutics$137.27M0.42-$76.42M-$14.59-0.45 Does the media prefer HUMA or KPTI? In the previous week, Karyopharm Therapeutics had 2 more articles in the media than Humacyte. MarketBeat recorded 5 mentions for Karyopharm Therapeutics and 3 mentions for Humacyte. Humacyte's average media sentiment score of 1.82 beat Karyopharm Therapeutics' score of 0.66 indicating that Humacyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Karyopharm Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend HUMA or KPTI? Humacyte currently has a consensus target price of $9.75, indicating a potential upside of 561.02%. Karyopharm Therapeutics has a consensus target price of $34.00, indicating a potential upside of 417.11%. Given Humacyte's stronger consensus rating and higher probable upside, research analysts plainly believe Humacyte is more favorable than Karyopharm Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Karyopharm Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is HUMA or KPTI more profitable? Humacyte has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -90.02%. Company Net Margins Return on Equity Return on Assets HumacyteN/A N/A -78.26% Karyopharm Therapeutics -90.02%N/A -84.28% SummaryHumacyte beats Karyopharm Therapeutics on 10 of the 15 factors compared between the two stocks. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.58M$2.84B$5.82B$10.17BDividend YieldN/A56.65%5.69%4.60%P/E Ratio-0.4523.5974.6725.98Price / Sales0.42544.01454.5485.61Price / CashN/A169.2537.0859.91Price / Book-0.305.3712.186.31Net Income-$76.42M$32.95M$3.29B$270.86M7 Day Performance-0.38%1.43%1.08%3.46%1 Month Performance63.56%8.48%7.32%6.57%1 Year Performance-40.43%0.53%63.11%28.39% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics3.8894 of 5 stars$6.58-1.0%$34.00+417.1%-39.8%$56.58M$137.27M-0.45380HUMAHumacyte3.0665 of 5 stars$1.55-1.9%$9.75+529.0%-73.6%$245.48M$1.57M-3.44150Positive NewsSGMTSagimet Biosciences3.2325 of 5 stars$7.51-0.7%$25.67+241.8%+87.2%$244.24M$2M-4.108ALECAlector3.9566 of 5 stars$2.35-1.7%$4.17+77.3%-50.6%$237.85M$100.56M-2.03270Positive NewsPRQRProQR Therapeutics2.6129 of 5 stars$2.25+2.7%$8.00+255.6%+18.4%$236.73M$20.46M-4.89180Short Interest ↑IMMPPrima BioMed1.4566 of 5 stars$1.61-3.0%$7.00+334.8%-35.9%$236.33M$5.14M0.002,021News CoverageENGNenGene2.6533 of 5 stars$4.62-2.7%$23.29+404.0%-9.6%$236.11MN/A-2.8031Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionSOPHSOPHiA GENETICS2.0134 of 5 stars$3.46+4.5%$8.00+131.2%-20.0%$233.82M$65.17M-7.86520OGIOrganigram Global1.2883 of 5 stars$1.73flatN/A-10.8%$231.91M$117.47M34.61860Positive NewsGap UpTKNOAlpha Teknova2.8372 of 5 stars$4.32+0.2%$10.00+131.5%-4.7%$231.19M$37.74M-10.29240Positive NewsEDITEditas Medicine4.3563 of 5 stars$2.57-3.0%$5.10+98.4%-28.3%$231.10M$32.31M-0.90230 Related Companies and Tools Related Companies Humacyte Competitors Sagimet Biosciences Competitors Alector Competitors ProQR Therapeutics Competitors Prima BioMed Competitors enGene Competitors SOPHiA GENETICS Competitors Organigram Global Competitors Alpha Teknova Competitors Editas Medicine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPTI) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredElon’s new AI play could hand regular Americans a Tesla‑like paydayElon Musk just launched his boldest AI project yet... And if history is any guide — it could make early inv...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KPTI Stock Alerts